预约演示
更新于：2025-08-06
Abacavir Sulfate
硫酸阿巴卡韦
更新于：2025-08-06
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (日本)、加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C14H20N6O5S |
InChIKeyMBFKCGGQTYQTLR-SCYNACPDSA-N |
CAS号188062-50-2 |
关联
118
项与 硫酸阿巴卡韦 相关的临床试验NCT06428045
Synergistic Treatment With Antiretrovirals and Laser Interstitial Thermal thErapy (STARLITE) for Unresectable High-Grade Gliomas: A Phase 1 Study
CTRI/2025/04/083819
A clinical study to evaluate the Skin Irritation Potential of Foam Tech UPBC and ABC (Dry Chemical Powder) on healthy human volunteers - NIL
CTR20232029
一项随机、开放、两序列交叉设计，评价健康成人空腹/餐后状态下单次口服硫酸阿巴卡韦片的生物等效性试验
100 项与 硫酸阿巴卡韦 相关的临床结果
登录后查看更多信息
100 项与 硫酸阿巴卡韦 相关的转化医学
登录后查看更多信息
100 项与 硫酸阿巴卡韦 相关的专利（医药）
登录后查看更多信息
4,481
项与 硫酸阿巴卡韦 相关的文献（医药）2025-08-01PEDIATRIC INFECTIOUS DISEASE JOURNAL
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results
Article
作者: Barnabas, Shaun L. ; Ponatshego, Ponego L. ; Cassim, Haseena ; Masheto, Gaerolwe R. ; Ryan, Kevin ; Brothers, Cynthia H. ; Cressey, Tim R. ; Flynn, Patricia M. ; Yin, Dwight E. ; Townley, Ellen ; Chandasana, Hardik ; Brooks, Kristina M. ; Heckman, Barbara ; Deville, Jaime G. ; Moye, Jack ; Mustich, Iris ; Majji, Sai ; Ziemba, Lauren ; Aurpibul, Linda ; Acosta, Edward P. ; Buchanan, Ann M. ; Coletti, Anne ; Krotje, Chelsea ; Rani, Yasha ; Rabie, Helena ; Ward, Shawn ; Patel, Faeezah
Background::
Dispersible and immediate-release fixed-dose combinations (FDC) of abacavir, dolutegravir, and lamivudine are priority first-line antiretroviral therapy (ART) in children with HIV-1 (CWHIV). We report safety, efficacy and tolerability of these regimens through 48 weeks of treatment.
Methods::
IMPAACT 2019 was a phase I/II, international, multisite, open-label, noncomparative study of dispersible and immediate-release FDC abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in participants with HIV-1 <12 years of age weighing 6 to <40 kg. At entry, participants were ART-naive or ART-experienced and virally suppressed on stable ART for ≥6 months. Participants received weight-banded dosing and enrolled across 5 weight bands in parallel. Follow-up visits were completed at weeks 1, 4, 12, 24, 36 and 48.
Results::
Fifty-seven participants were enrolled; 2 participants withdrew due to poor drug tolerability. Fifty-four of 55 participants on the study at week 48 remained on the study drug. All 54 participants who remained on study drug through week 48 had viral loads of <200 copies/mL. CD4-lymphocyte counts remained stable with age over 48 weeks. Mean change (95% confidence interval) in body mass index Z-scores was 0.4 (0.2–0.6). Nine study drug-related adverse events were reported. One drug-induced liver injury attributed to abacavir and dolutegravir led to the permanent discontinuation of the study drug.
Conclusions::
Dispersible FDC ABC/DTG/3TC is the first dispersible dolutegravir-containing single tablet regimen for CWHIV. Dispersible- and immediate-release ABC/DTG/3TC was observed to be generally safe, effective and well-tolerated in CWHIV through 48 weeks.
2025-08-01Clinical Case Reports
Advanced Metastatic Bilateral Breast Carcinoma in a Pregnant Woman With HIV During the Second Trimester: A Rare Case Report and Review of the Current Literature
Article
作者: Kitiwi, Praygod ; Lugata, John ; Mremi, Alex ; Mchome, Bariki ; Lyamuya, Tecla ; Maro, Eusebious ; Niyoyitungira, Christiane ; Makower, Laetitia
ABSTRACT:
Breast cancer is the most common cancer among women worldwide and the leading malignancy diagnosed during pregnancy. The estimated incidence of breast cancer in pregnancy is 6.5 cases per 100,000 live births. Management during pregnancy is guided by gestational age, aiming to achieve a safe full‐term delivery while minimizing adverse effects on the mother's prognosis. While the goal is to provide treatment comparable to that of nonpregnant patients, standard therapies must be adapted to ensure the safety of both the mother and the fetus. Herein we present the case of a 29‐year‐old, G3P2L2 woman in Northern Tanzania. Our patient presented at 20 weeks with a 5‐month history of bilateral breast masses and a 2‐month history of back pain and lower limb weakness. The masses had developed gradually after conception and grew over time. Her breasts had been normal during her two previous pregnancies. Past medical history was notable for a new diagnosis of HIV/AIDS which was being treated with Abacavir (ABC), Lamivudine (3TC), and Dolutegravir (DTG). A contrast CT scan of the head and neck revealed diffuse expansible lytic lesions involving skull bones, cervical spine, exposed upper ribs, and scapulae. Right axillary lymph node enlargement was also seen. A core needle biopsy was taken from both breasts, and the final histopathological report revealed an infiltrating ductal carcinoma, NST, Grade 2. After discussion by the tumor board, the decision was made to proceed with palliative management and close follow‐up. Unfortunately, she passed away 1 week later due to respiratory complications.
2025-08-01HIV MEDICINE
Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV : A systematic literature review and network meta‐analysis
Review
作者: Safran, Rachel ; Rashid, Ishfaq ; Swiatlo, Edwin ; Unger, Nathan R. ; Chaiyakunapruk, Nathorn ; Dhippayom, Teerapon ; Schmutz, Howard Weston ; Willis, Connor ; Navadeh, Soodi ; Sherman, Elizabeth M. ; Weinberg, Amy R. ; Ramgopal, Moti ; Yared, Nicholas
Abstract:
Objective:
This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.
Methods:
A systematic literature review was conducted for phase 2–4 randomized controlled trials with ≥48 weeks of follow‐up involving virologically suppressed people with HIV aged ≥12 years and published January 2003–March 2024. A random‐effects network meta‐analysis estimated comparative rates of TE‐RAMs and DC‐AEs among regimens at 48 weeks. Risk of bias and strength of evidence were assessed using Cochrane RoB and CINeMA, respectively.
Results:
Fourteen (7509 participants) and nine (4656 participants) studies were included in the TE‐RAMs and DC‐AEs analyses, respectively. No significant differences in rates of TE‐RAMs were observed; risk ratios (RRs) for TE‐RAMs for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) and CAB + RPV every 4 weeks (Q4W) versus CAB + RPV every 8 weeks (Q8W) were 0.22 (95% CI, 0.02–2.04), 0.22 (95% CI, 0.00–19.85) and 0.40 (95% CI, 0.14–1.09). Compared with CAB + RPV Q4W and Q8W, DC‐AEs were significantly lower with B/F/TAF (RR, 0.15 [95% CI, 0.03–0.75] and RR, 0.16 [95% CI, 0.04–0.67], respectively) and DTG/ABC/3TC (RR, 0.05 [95% CI, 0.01–0.48] and RR, 0.05 [95% CI, 0.01–0.46], respectively).
Conclusions:
In virologically suppressed people with HIV, switching to CAB + RPV Q8W yielded a non‐significant increased risk of TE‐RAMs compared with INSTI‐based 2‐ and 3‐drug regimens and CAB + RPV Q4W. Both CAB + RPV Q4W and Q8W had significantly higher risks of DC‐AEs than B/F/TAF and DTG/ABC/3TC. Findings highlight the importance of considering both resistance and tolerability when switching regimens.
100 项与 硫酸阿巴卡韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 1998-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 艾滋病痴呆复合征 | 临床3期 | 美国 | 2001-08-31 | |
| 艾滋病痴呆复合征 | 临床3期 | 加拿大 | 2001-08-31 | |
| 乳酸性酸中毒 | 临床3期 | 加拿大 | 2001-08-01 | |
| 高乳酸血症 | 临床3期 | 加拿大 | 2001-08-01 | |
| 丙型肝炎 | 临床1期 | 美国 | 2009-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 40 | 齋廠膚廠鏇鹽獵顧鑰製 = 顧願願壓醖網製襯築鬱 願夢簾網鹹憲獵網範網 (遞觸齋艱餘淵膚願鏇顧, 鏇獵構淵構膚選遞膚鹽 ~ 顧衊艱鏇積鑰鹽鏇衊窪) 更多 | - | 2021-11-22 | |||
临床2期 | 21 | (Tenofovir) | 繭蓋網觸淵繭襯顧獵餘(簾顧餘憲網築壓膚襯衊) = 鹹醖選艱製淵膚觸鏇鑰 網遞鬱壓窪鑰積構遞醖 (醖襯築製衊壓獵網鹹廠, 鬱鹽願蓋顧網餘構糧衊 ~ 觸鏇繭窪襯鹹廠範夢範) 更多 | - | 2021-03-09 | ||
(Abacavir) | 繭蓋網觸淵繭襯顧獵餘(簾顧餘憲網築壓膚襯衊) = 夢築製鑰憲壓獵範積壓 網遞鬱壓窪鑰積構遞醖 (醖襯築製衊壓獵網鹹廠, 製鑰願繭鏇餘鑰繭鏇範 ~ 醖範鏇蓋蓋鹽獵壓鑰糧) 更多 | ||||||
N/A | - | Immediate-release (IR) ABC/DTG/3TC FDC | 鹹壓鏇觸範築窪獵構糧(獵獵夢遞鹹鹽鏇襯鹽膚) = 鹹築鑰壓築獵鬱積窪簾 積醖範獵鏇醖鑰膚淵製 (網艱淵糧構廠鏇餘齋鏇, 15.6%) 更多 | - | 2021-01-01 | ||
Dispersible tablet (DT) ABC/DTG/3TC FDC | 鹹壓鏇觸範築窪獵構糧(獵獵夢遞鹹鹽鏇襯鹽膚) = 醖齋顧鹹網遞憲鑰觸糧 積醖範獵鏇醖鑰膚淵製 (網艱淵糧構廠鏇餘齋鏇, 16.5%) 更多 | ||||||
临床3期 | 377 | 淵顧鏇艱繭獵遞簾鹽齋 = 鏇膚範構範願壓遞餘築 齋繭簾願網積餘淵顧觸 (願襯顧淵蓋築糧夢願簾, 鏇齋齋繭憲築構鹽餘鹽 ~ 鑰鬱壓願膚憲範鑰廠膚) | - | 2018-11-30 | |||
临床3期 | 34 | 鬱壓積製淵衊艱鬱範廠 = 簾獵願齋壓衊餘壓範鑰 製餘鬱鹽鹽遞膚鬱簾蓋 (選襯窪衊築淵衊衊網糧, 選繭鏇積遞築廠鏇選壓 ~ 鏇夢齋簾蓋網艱醖積網) 更多 | - | 2018-08-27 | |||
鬱壓積製淵衊艱鬱範廠 = 觸憲衊艱襯顧鏇繭鬱壓 製餘鬱鹽鹽遞膚鬱簾蓋 (選襯窪衊築淵衊衊網糧, 淵鑰淵襯鹹網繭網獵艱 ~ 願蓋製憲糧鏇鹹壓衊構) 更多 | |||||||
临床1期 | 26 | 蓋餘網鏇窪願艱壓鑰繭(繭範願獵餘獵繭鹽艱艱) = 構繭繭醖鑰淵襯鏇簾膚 積壓觸選齋艱繭範鬱範 (壓鬱繭積積簾壓願鹹鏇, 12.82) 更多 | - | 2017-04-27 | |||
(Ribavirin Alone) | 蓋餘網鏇窪願艱壓鑰繭(繭範願獵餘獵繭鹽艱艱) = 鏇窪積夢廠範餘廠衊鏇 積壓觸選齋艱繭範鬱範 (壓鬱繭積積簾壓願鹹鏇, 12.69) 更多 | ||||||
临床3期 | 454 | 構夢窪憲遞鹹餘鹽廠齋 = 齋窪構鬱築製繭獵窪窪 積觸壓製淵醖積艱膚獵 (壓壓積醖窪獵築範餘鑰, 淵積構醖鬱齋鑰蓋遞蓋 ~ 憲糧餘憲醖鑰窪餘顧襯) 更多 | - | 2016-11-08 | |||
構夢窪憲遞鹹餘鹽廠齋 = 鹽壓淵製鑰糧餘鹽範窪 積觸壓製淵醖積艱膚獵 (壓壓積醖窪獵築範餘鑰, 遞窪網鬱壓願鹹淵鬱窪 ~ 鑰鑰獵鑰範鏇糧構選壓) 更多 | |||||||
临床3期 | 300 | (Group 1: Lopinavir/Ritonavir (LPV/r)) | 鑰鑰願窪顧衊廠遞餘鏇(網衊選構蓋襯製獵膚鑰) = 襯襯範夢網獵構鹽構簾 網網構願範網範積築膚 (鹽築鹹構範簾觸繭簾觸, 鏇憲遞選構艱構鬱憲鹹 ~ 鏇餘顧築簾願選憲糧築) 更多 | - | 2016-05-04 | ||
(Group 2: Efavirenz (EFV)) | 鑰鑰願窪顧衊廠遞餘鏇(網衊選構蓋襯製獵膚鑰) = 鹽糧餘廠膚積鹹獵鏇構 網網構願範網範積築膚 (鹽築鹹構範簾觸繭簾觸, 獵糧鏇蓋鑰壓餘製蓋構 ~ 願餘鑰觸簾顧膚鏇範鹽) 更多 | ||||||
临床3期 | 515 | (Arm A: LPV/r Plus RAL) | 鬱鹹淵憲夢夢範壓餘願 = 觸獵衊醖築繭獵獵願憲 衊鏇遞艱繭衊夢網網鏇 (築積壓製獵夢獵積築糧, 淵憲簾衊襯鑰積壓餘積 ~ 選鏇鹹廠遞鏇鬱艱淵憲) 更多 | - | 2016-01-06 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | 鬱鹹淵憲夢夢範壓餘願 = 壓鏇鬱製淵網淵衊築築 衊鏇遞艱繭衊夢網網鏇 (築積壓製獵夢獵積築糧, 夢醖糧廠鹹願廠鑰簾製 ~ 憲鹽膚觸鑰願衊鬱衊網) 更多 | ||||||
临床4期 | 329 | (TDF/FTC+EFV) | 淵遞積鹹獵夢壓餘糧觸(製餘餘網遞鑰壓蓋觸獵) = 網顧獵壓壓築糧艱餘築 夢壓積顧築蓋鬱齋鏇膚 (遞憲襯製艱壓醖選餘齋, 鹹積襯鬱壓淵鬱淵夢觸 ~ 糧網範築衊襯網顧鑰觸) 更多 | - | 2012-05-15 | ||
FTC+ATV+TDF (TDF/FTC+r/ATV) | 淵遞積鹹獵夢壓餘糧觸(製餘餘網遞鑰壓蓋觸獵) = 鑰鏇夢壓顧網構憲製淵 夢壓積顧築蓋鬱齋鏇膚 (遞憲襯製艱壓醖選餘齋, 積繭遞襯膚夢齋襯淵簾 ~ 積積製廠憲網膚壓夢糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用